FinancialBuzz.com’s latest
The Buzz Show: Featuring Our Corporate News Recap on “Second Sight Medical Receives FDA Approval for the Argus 2s Retinal Prosthesis System”
Second Sight Medical
(NASDAQ: EYES) Products surged just under 60% in premarket trading after the company announced the U.S. Food and Drug Administration has approved the Argus 2s Retinal Prosthesis System.
The Company expects that the redesigned set of external hardware initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa, will be adapted to be the external system for the next generation Orion Visual Cortical Prosthesis System, currently under development.
Second Sight Medical Products Inc. plans to combine with Pixium Vision SA, a French company, to pursue their common quest to develop bionic vision systems.
The Sylmar company is working on its next-generation vision prosthetic, called the Orion system, which is complementary to a retinal-based system being made by Pixium.
According to Acting Chief Executive Matthew Pfeffer, both companies have been aware of each other for many years and have had interactions in the past. The transaction will secure the future of both companies by reducing overhead costs and creating synergies, he said.
Read the full story in the March 1 issue of the San Fernando Valley Business Journal.
Retinitis Pigmentosa benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Cash position at 31 December 2020: â¬10.6 million Cash runway to end of 2021 PRIMAvera European pivotal study of Prima System initiated in Q4 2020 Paris, 19 February 2021 â 7.00 a.m. CET - Pixium Vision (FR0011950641 - PIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, announces its financial results for 2020. The 2020 financial statements were approved by Pixium Vision s Board of Directors at its meeting on 18 February 2021.
Lloyd Diamond, CEO of Pixium Vision commented We continued in 2020 to deliver on our plan of transitioning Pixium Vision from a research project to a commercially oriented company. We progressed our innovative Prima System to the last step of clinical development in Europe by initiating the PRIMAvera pivotal study and strengthened our presence in the US in anticipation of increasing clinical development in this key market. We are well positio
Retinal Implants Market Worldwide Key Players Forecasts By Revenue, Growth Rate Till 2023 sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.